EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Adherence in Hepatitis C Virus Treatment: What We Know

Steven L Flamm, Alessandra Mangia

Seminars in Liver Disease · 01.05.2024 · 44 (02) · 258-271

DOI: 10.1055/a-2313-0111 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.05.2024. Verfasst von Steven L Flamm und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive Diseases and Nutrition, Rush University Medical School, Chicago, Illinois. Hauptthemen laut MEDLINE: Antiviral Agents, Medication Adherence, Sustained Virologic Response. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although therapy with direct-acting antiviral (DAA) agents achieves high hepatitis C virus (HCV) cure rates and is forgiving of missed doses, certain patient populations, such as people who inject drugs (PWID), are often denied therapy because of a perceived high risk of nonadherence. However, a relationship between adherence to DAAs for various patient populations and efficacy has not been well defined. The lack of a standardized method for evaluating adherence complicates making comparisons between studies, making it difficult to develop and implement novel measures that may improve adherent behavior. Traditional methods for assessing adherence may overestimate medication adherence, while newer, technology-based methods may assist with accurately assessing and maintaining patient adherence to therapy. Data demonstrate that special populations of patients with HCV, such as PWID, can be successfully treated, with relatively high rates of sustained virologic response (SVR) despite less-than-optimal adherence. While rates of adherence, and subsequently SVR, can be improved, antiviral therapy should not be withheld because of fear of nonadherence. This article addresses medication adherence and forgiveness of DAA regimens, such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir, in different patient populations with HCV. Considerations in evaluating adherence in HCV therapy and available methods for assessing adherence are detailed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsMedication AdherenceSustained Virologic ResponseHumansHepatitis CHepacivirusTreatment OutcomeHepatitis C, ChronicDrug Therapy, CombinationSubstance Abuse, Intravenous

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Digestive Diseases and Nutrition, Rush University Medical School, Chicago, Illinois.
  • Department of Medical Sciences Hepatology, Fondazione Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy.

Förderung

  • Gilead Sciences

Zitieren

APA

Flamm, S. L., & Mangia, A. (2024). Adherence in Hepatitis C Virus Treatment: What We Know. Seminars in Liver Disease, 44(02), 258-271. https://doi.org/10.1055/a-2313-0111

Vancouver

Flamm SL, Mangia A. Adherence in Hepatitis C Virus Treatment: What We Know. Seminars in Liver Disease. 2024;44(02):258-271. doi:10.1055/a-2313-0111

BibTeX
@article{Flamm2024,
  author = {Flamm, Steven L and Mangia, Alessandra},
  title = {Adherence in Hepatitis C Virus Treatment: What We Know},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {02},
  pages = {258--271},
  doi = {10.1055/a-2313-0111}
}
Kostenlos starten →